Trials / Completed
CompletedNCT03802617
A Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus.
A Phase II Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 247 (actual)
- Sponsor
- Kissei Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
Double-blind, Placebo-controlled study to evaluate the dose-response relationship of safety, efficacy and pharmacokinetics of MA13A9 in hemodialysis patients with pruritus.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MR13A9 | Intravenous administration |
| DRUG | Placebo | Intravenous administration |
Timeline
- Start date
- 2019-02-01
- Primary completion
- 2019-10-22
- Completion
- 2019-10-22
- First posted
- 2019-01-14
- Last updated
- 2025-12-05
- Results posted
- 2025-12-05
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT03802617. Inclusion in this directory is not an endorsement.